People · Operator
Named in public records as an officer, director or promoter · active 2017–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Hexagon Bio Inc. | — | Biotechnology | Series C | $148.6M | $1.2B | 2017 |
Colin James Bell Harvey at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Colin James Bell Harvey on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Goeddel | 1 | 10 |
| Alex Kolicich | 1 | 8 |
| Jakob Loven | 1 | 2 |
| Brian Naughton | 1 | 2 |
| Brian T Naughton | 1 | 1 |
| David T Goeddel | 1 | 1 |
| Mridula T Ray | 1 | 1 |
| Maureen E Hillenmeyer | 1 | 1 |
| Maureen Hillenmeyer | 1 | 1 |
| Juan Jaen | 1 | 1 |
| Mridula Ray | 1 | 1 |
| Alex Bell Kolicich | 1 | 1 |
| Alex Bell Kolich | 1 | 1 |
| Juan T Jaen | 1 | 1 |
| Alex T Kolicich | 1 | 1 |
| Jakob T Loven | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.